Tuesday 17 March 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • JPMA sets up tax-related task force

JPMA sets up tax-related task force

23 February 2009

The Japan Pharmaceutical Manufacturers Association has created a task force on tax-related issue under its Council on Planning and Policy. It  hopes to have a draft petition for fiscal year 2010 reform around May. A  main plank of its petition will be a request for the government to  change the R&D Promotion Tax, which is now limited to two years, to a  permanent system and wider application.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

By George Medicines, another GMRx2 deal
Pharmaceutical
By George Medicines, another GMRx2 deal
16 March 2026
Pharmaceutical
Deal gives Sentynl shot at second HGPS treatment
16 March 2026
Generics
Middle East conflict threatens India’s pharma exports, losses could top $541 million
16 March 2026
Biotechnology
Continued positive trial results for CytomX’s varsetatug masetecan
16 March 2026
Pharmaceutical
Sovereign wealth funds: the new life science kingmakers?
16 March 2026
Biotechnology
Almirall Phase III pediatric eczema results ‘meaningful’
16 March 2026
Pharmaceutical
New Kerendia top-line data for adults with non-diabetic CKD
16 March 2026


Company Spotlight

Purple Biotech
A clinical-stage biotechnology company developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. Purple Biotech focuses on immuno-oncology and targeted cancer therapies designed to enhance immune responses against solid tumors.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze